This study investigated the complex interplay between two gut hormones, glucagon-like peptide-1 (GLP-1) and ghrelin and their role in the development of alcohol-associated liver disease (ALD). Previous studies conducted in our laboratory and others have shown that chronic alcohol exposure leads to increased serum ghrelin and GLP-1 levels. Paradoxically, despite increased GLP-1, insulin resistance and disrupted hepatic lipid metabolism was noted in chronic ethanol fed animals. These results suggested impaired GLP-1-mediated protective function in the presence of high ghrelin. Our recent studies also revealed that growth hormone secretagogue receptor (GHSR, which is the ghrelin receptor) knockout (GHSR-KO) rats fed ethanol were more insulin sensitive and were resistant to develop ALD despite reduced serum GLP-1 compared to ethanol-fed wildtypes. Based on these considerations, we hypothesized that alcohol-induced increases in ghrelin-GHSR interaction impairs GLP-1-mediated functions. We employed both in vivo and in vitro approaches, including chronic ethanol feeding of wild-type and GHSR-KO rats, ghrelin administration to chow-fed rats, GSHR and GLP-1 receptor (GLP-1R)-transfected hepatocytes, murine enteroendocrine GLUTag and HEK293T cells utilizing several techniques to test our hypothesis. Chronic ethanol feeding in wildtype rats increased GLP-1 and GLP-1R levels, while ethanol-fed GHSR-KO rats did not show this increase. Ghrelin promoted GHSR and GLP-1R interaction/dimerization, thereby reducing GLP-1 effects. Furthermore, in-silico molecular docking analysis identified specific amino acid residues in the transmembrane regions of both receptors that are predicted to mediate this interaction. Alcohol-induced increases in ghrelin modulate GLP-1-mediated functions through GHSR-GLP-1R interactions. Targeting this interaction could offer a potential therapeutic strategy for ALD.
Characterizing ghrelin's role in dysregulating GLP-1-mediated function and promoting the development of alcohol-associated liver disease.
阅读:1
作者:Mahalingam Sundararajan, Bellamkonda Ramesh, Kharbanda Kusum K, Ethiraj Ojeshvi, Nagarajan Nagasundaram, Guda Chittibabu, Sharma Kanika, Schott Micah B, Casey Carol A, Leggio Lorenzo, Rasineni Karuna
| 期刊: | Biomedicine & Pharmacotherapy | 影响因子: | 7.500 |
| 时间: | 2026 | 起止号: | 2026 Feb;195:118924 |
| doi: | 10.1016/j.biopha.2025.118924 | ||
特别声明
1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。
2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。
3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。
4、投稿及合作请联系:info@biocloudy.com。
